Methoxsalen Macopharma (Methoxsalen)

Methoxsalen intercalates into DNA and, when activated by UVA light, forms covalent cross‑links with pyrimidine bases. These cross‑links inhibit DNA synthesis and cell proliferation, leading to reduced epidermal growth in psoriasis and modulation of melanocyte activity that supports repigmentation in vitiligo.

The dosage of Methoxsalen Macopharma is determined by the prescribing clinician based on the specific condition, patient characteristics, and treatment protocol. Only a qualified healthcare professional can set the appropriate dose and schedule for each individual patient.

Safety data for methoxsalen in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Methoxsalen is one of several psoralens used in PUVA therapy; another common agent is 8‑methoxypsoralen (Trioxsalen). Both have similar mechanisms, but methoxsalen is more widely used in Europe and has an established safety profile. Choice between agents often depends on regional practice, formulation availability, and specific patient tolerance.

Methoxsalen Macopharma should be stored at ambient temperature, below 25 °C, in its original packaging. The container must be kept closed, protected from moisture and direct light to maintain stability. No refrigeration is required for this extracorporeal preparation.

The product is intended for extracorporeal use. Typically, a measured dose is applied topically to the skin surface or administered systemically shortly before exposure to a controlled UVA light source. The timing and method of administration are defined by the treating physician’s protocol.

Serious risks include severe phototoxic reactions such as blistering and extensive skin damage, hepatotoxicity indicated by marked liver enzyme elevations, and rare but life‑threatening conditions like Stevens‑Johnson syndrome. Patients should be monitored closely for any signs of these reactions during and after treatment.

Methoxsalen is contraindicated in patients with a history of severe photosensitivity, active skin cancers, uncontrolled liver disease, or known hypersensitivity to psoralens. It should also be avoided in individuals taking other strong photosensitizing medications unless the prescriber determines that benefits outweigh risks.